Stenotrophomonas maltophilia: Results of Antimicrobial Susceptibility Testing and In Vitro Activity of the Combination of Ceftazidime and Moxifloxacin

Abstract

Objective: Recommended combination for the treatment of serious Stenotrophomonas maltophilia infections is ticarcillin-clavulanate and co-trimoxazole (SXT). However, first agent is not available in our country, and the second component may be a matter of antimicrobial resistance or intolerance. Therefore, we aimed to evaluate antimicrobial susceptibility testing results of S. maltophilia and in vitro activity of ceftazidime and moxifloxacin as a potential therapeutic alternative.